A Prognostic Predictive System Based on Deep Learning for Locoregionally Advanced Nasopharyngeal Carcinoma. (24th September 2020)

• Record Type: Journal Article
• Authors: Qiang, Mengyun; Li, Chaofeng; Sun, Yuyao; Sun, Ying; Ke, Liangru; Xie, Chuanmiao; Zhang, Tao; Zou, Yujian; Qiu, Wenze; Gao, Mingyong; Li, Yingxue; Li, Xiang; Zhan, Zejiang; Liu, Kuiyuan; Chen, Xi; Liang, Chixiong; Chen, Qiuyan; Mai, Haiqiang; Xie, Guotong; Guo, Xiang; Lv, Xing
• Is Part Of: Journal of the National Cancer Institute. Volume 113:Number 5(2021)
• Page Start: 606
• Page End: 615
• Publication Date: 2020-09-24
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djaa149
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Background: Images from magnetic resonance imaging (MRI) are crucial unstructured data for prognostic evaluation in nasopharyngeal carcinoma (NPC). We developed and validated a prognostic system based on the MRI features and clinical data of locoregionally advanced NPC (LA-NPC) patients to distinguish low-risk patients with LA-NPC for whom concurrent chemoradiotherapy (CCRT) is sufficient. Methods: This multicenter, retrospective study included 3444 patients with LA-NPC from January 1, 2010, to January 31, 2017. A 3-dimensional convolutional neural network was used to learn the image features from pretreatment MRI images. An eXtreme Gradient Boosting model was trained with the MRI features and clinical data to assign an overall score to each patient. Comprehensive evaluations were implemented to assess the performance of the predictive system. We applied the overall score to distinguish high-risk patients from low-risk patients. The clinical benefit of induction chemotherapy (IC) was analyzed in each risk group by survival curves. Results: We constructed a prognostic system displaying a concordance index of 0.776 (95% confidence interval [CI] = 0.746 to 0.806) for the internal validation cohort and 0.757 (95% CI = 0.695 to 0.819), 0.719 (95% CI = 0.650 to 0.789), and 0.746 (95% CI = 0.699 to 0.793) for the 3 external validation cohorts, which presented a statistically significant improvement compared with the conventional TNM staging system. In the high-risk group, patients who received induction chemotherapy plus CCRT had better outcomes than patients who received CCRT alone, whereas there was no statistically significant difference in the low-risk group. Conclusions: The proposed framework can capture more complex and heterogeneous information to predict the prognosis of patients with LA-NPC and potentially contribute to clinical decision making.